AmCad BioMed

Notice of 2026 Annual General Shareholders' Meeting

Form of meeting：Physical Meeting
Meeting Time：9:00a.m., Friday , June 12, 2026
Meeting Place：3rd Fl., No.10 Shih-er Rd., Yangmei District, Taoyuan City

AGENDA

I. Chairman to announce the commencement of meeting.

II. Report Items

1. The 2025 Business Report.
2. The 2025 Audit Committee's Review Report.
3. Report on the Execution Status of the Private Placement of Common Shares Approved at the 2025 Annual General Shareholders' Meeting.
4. Implementation Status of the Sound Business Operation Plan; Progress of Fund Utilization from the 2015 and 2024 Cash Capital Increases; Actual Use of Funds; and Evaluation Results on the Reasonableness of Each Expenditure Item as Assessed by the Underwriter.
5. Report on the Revision to the Sustainable Development Best Practice Principles.

III. Acknowledged Items

1. Adoption of 2025 the Financial Statements and Business Report.
2. Adoption of the Proposal for 2025 Deficit Compensation.

IV. Discussion Item

Discussion on the Proposal for Private Placement of Common Shares through Cash Capital Increase.

V. Election Item

Elections of board directors.

VI. Other Item

Proposal to Release the Prohibition on Directors and Their Representatives from Participation in Competitive Business.

VII. Extemporary Motions

VIII. Adjournment

Notice of Meeting

I. The 2026 Annual General Shareholders' Meeting will be convened at 9:00 a.m. on Friday, June 12, 2026, at 3rd Fl., No.10 Shih-er Rd., Yangmei District, Taoyuan City. Shareholder registration will begin 30 minutes prior to the meeting. The main agenda items are as follows: (I) Report Items: 1. The 2025 Business Report; 2. The 2025 Audit Committee's Review Report; 3. Report on the Execution Status of the Private Placement of Common Shares Approved at the 2025 Annual General Shareholders' Meeting; 4. Implementation Status of the Sound Business Operation Plan; Progress of Fund Utilization from the 2015 and 2024 Cash Capital Increases; Actual Use of Funds; and Evaluation Results on the Reasonableness of Each Expenditure Item as Assessed by the Underwriter; and 5. Report on the Revision to the Sustainable Development Best Practice Principles. (II) Acknowledged Items: 1. Adoption of 2025 the Financial Statements and Business Report; and 2. Adoption of the Proposal for 2025 Deficit Compensation. (III) Discussion Item: Discussion on the Proposal for Private Placement of Common Shares through Cash Capital Increase. (IV) Election Item: Elections of board directors. (V) Other Item: Proposal to Release the Prohibition on Directors and Their Representatives from Participation in Competitive Business. (VI) Extemporary Motions.

II. For details regarding the Company's "Private Placement of Common Shares through Capital Increase," please refer to Attachment 1.

III. At this shareholders' meeting, eleven directors, including four independent directors, will be elected under the candidate nomination system. The list of director candidates is as follows: Lee Yi-Li; Lee Yi-Ling, representative of Phytohealth Corp.,; Chang King-Jen; Sheu Jin-Chuan, representative of Maywufa Company Ltd.; Chen Wal-Ter, representative of PhytoHealth Corp.,; Chiou Shu-Ti, representative of PhytoHealth Corp.,; Gary T. Tseng, representative of Maywufa Company Ltd. The list of independent director candidates is as follows: Chang Ching-Tian, Huang Weng-Foung, Li Hsueh-Yu, and Lin She-Yi. For information on the candidates' educational backgrounds, professional experience, and other relevant details, please visit the Market Observation Post System website (https://mops.twse.com.tw), select "Shareholders' Meeting/Dividends" under "Aggregated Reports," then click "Announcements Related to the Election of Directors under the Candidate Nomination System," and enter the relevant search criteria.

IV. If there are any reasons for convening this shareholders' meeting as prescribed under Article 172 of the Company Act, the main contents thereof may be accessed on the Market Observation Post System website (https://mops.twse.com.tw). Please select "Electronic Document Download" under "Single Company," then click "Annual Reports and Shareholders' Meeting Related Information," enter the company code or abbreviated company name and the relevant year, and select "Meeting Handbook and Supplemental Meeting Information" or "Reference Materials for Shareholders' Meeting Proposals" to search for the relevant information.

V. Pursuant to Article 165 of the Company Act, share transfer registration will be suspended from April 14, 2026 to June 12, 2026.

VI. In addition to the announcement made on the Market Observation Post System, this notice is hereby served upon you, together with one copy each of the shareholders' meeting attendance sign-in card and the proxy form. Your attention to this matter and attendance at the meeting would be greatly appreciated. If you will attend the meeting in person, please complete the attendance sign-in card in the third section; it is not necessary to mail it back. Please bring it with you to the meeting venue on the meeting date for registration and attendance. If you appoint a proxy to attend the meeting on your behalf, please complete the proxy form in the fourth section, fold and mail back the entire form, and ensure that it is delivered to the Stock Affairs Agency Department of Grand Fortune Securities Co., Ltd., the Company's stock affairs agent, at least five days before the meeting date. Upon verification of the information by the Stock Affairs Agency Department, an attendance sign-in card will be prepared and mailed to the appointed proxy for use in attending the shareholders' meeting. If the appointed proxy has not received the attendance sign-in card by the day before the meeting, the proxy may bring his/her identification document to the meeting venue on the meeting date to complete the attendance procedures.

VII. If there is any proxy solicitor for this shareholders' meeting, the Company will, in accordance with applicable regulations, compile and upload the written proxy solicitation materials to the Securities and Futures Institute (SFI) by May 12, 2026. The SFI website is https://free.sfi.org.tw. Investors may visit the website and enter the securities code under "Free Search of Proxy Solicitation Announcement Information" to search for the relevant information.

VIII. Shareholders may exercise their voting rights electronically at this shareholders' meeting. The voting period will be from May 13, 2026 to June 9, 2026. Please log in to Taiwan Depository & Clearing Corporation's "Shareholder e-Service" platform at https://stockservices.tdcc.com.tw, select "Electronic Voting," and proceed with voting in accordance with the relevant instructions.

IX. The institution responsible for proxy form verification for this shareholders' meeting is the Shareholder Services Department of Fu Bon Securities Co., Ltd.

X. Kindly take this matter into consideration and proceed accordingly.

To our esteemed shareholders,

Sincerely,
Board of Directors
AmCad BioMed Corporation

Attachment 1

The following are the relevant explanations regarding the Company's "Private Placement of Common Shares through Capital Increase"：

1. To accelerate product promotion and enhance the Company's revenue and profitability, it is proposed to conduct a private placement of common shares within a limit of no more than 15,000,000 shares.

2. Pursuant to Article 43-6 of the Securities and Exchange Act and the "Regulations Governing the Offering and Issuance of Securities by Securities Issuers," the following matters regarding the private placement of common shares are hereby explained：

(1)Basis and Reasonableness of the Pricing：

①The price per share for the private placement shall not be lower than 80% of the reference price. The reference price shall be the higher of the following two averages.

(a) The simple arithmetic average of the closing prices of the Company's common shares for either 1, 3, or 5 business days prior to the pricing date, adjusted for any ex-dividend and ex-rights effects, and reinstated for any capital reduction.

(b) The simple arithmetic average of the closing prices of the Company's common shares for the 30 business days prior to the pricing date, also adjusted for any ex-dividend and ex-rights effects, and reinstated for any capital reduction.

The actual pricing date and private placement price will be determined by the Board of Directors, within the authorized range approved by the shareholders' meeting, based on negotiations with specific investors in the future.

②In addition to complying with the relevant provisions of the "Regulations Governing the Offering and Issuance of Securities by Securities Issuers," the pricing rationale also considers that privately placed securities shall be subject to a three-year transfer restriction starting from the delivery date. Moreover, within this period, the securities may not be registered for public issuance or listed on the stock exchange. Therefore, the pricing is deemed reasonable.

(2)Method of Selecting Specific Investors：

①The private placement targets shall be limited to specific investors as defined in Article 43-6 of the Securities and Exchange Act and in accordance with the Financial Supervisory Commission's directive No. 1120383220 dated September 12, 2023

②The Company has not yet confirmed any subscribers for the private placement. However, if the subscribers are insiders or related parties, their selection method, purpose of participation, and relationship with the Company will be explained as follows：

Subscriber(s)	Selection Method and Purpose	Relationship with the Company
PhytoHealth Corp.	To ensure the long-term stability of the Company's operations	Parent company
Maywufa Company Limited.	To ensure the long-term stability of the Company's operations	Affiliates

Disclosure Requirements if the Subscriber is a Corporate Entity：

Corporate Subscriber	The names and shareholding percentages of its top ten shareholders		Relationship with the Company
	Name	Shareholding Percentage	
PhytoHealth Corp. (As recorded in the shareholders' register as of April 11, 2026)	Maywufa Company Ltd. Representative：Lee Chen-Chia	19.00% 0.15%	Corporate director Director
	Yun Cheng Investment Corporation	0.90%	NA
	Chen Qing-Tang	0.60%	NA
	Zheng An-Hang	0.55%	NA
	Wu Yu-Kun	0.53%	NA
	Chang Te-Rong	0.52%	NA
	Lu Xue-Chang	0.50%	NA

	Wu Zhao-Xiong	0.50%	NA
	National Defense Education Foundation Research Foundation	0.48%	NA
	Wu Li-Hua	0.47%	NA
Maywufa Company Limited (As recorded in the shareholders' register as of April 12, 2026)	Cheng Yi Investment Company Ltd. Representative：Lee Chen-Chia	17.75% 2.03%	NA Director
	Phytohealth Corp. Representative：Lee Yi-Li	12.59% 1.05%	Corporate Director Chairperson and CEO
	Li Ling Investment Company Ltd. Representative：Lee Chen-Chia	11.25% 2.03%	NA Director
	Chen Wen-Hwa	2.71%	NA
	Cheng Hsin Investment Company Ltd. Representative：Lee Chen-Chia	2.36% 2.03%	NA Director
	Lee Chen-Chia	2.03%	Director
	Lee Yi-Li	1.05%	Chairperson and CEO
	Yi Xin International Company Ltd. Representative：Lee Yu-Chia	0.84% 0.08%	NA NA
	Lin Ting-Chi	0.81%	NA
	Jhan Mao Enterprise Co., Ltd.	0.75%	NA

(3)Necessity of Conducting a Private Placement：

①Reason for Not Using a Public Offering：Taking into account the conditions of the capital market, timeliness, convenience, and cost-effectiveness of capital raising, the Company proposes to raise funds through a private placement at an appropriate time with specific investors. This approach is intended to facilitate a prompt injection of required capital.

②Private Placement Quota：The total number of shares to be privately placed shall not exceed 15,000,000 shares and shall be executed in one tranche within one year from the date of the shareholders' resolution.

③Purpose of Funds and Expected Benefits：

Proposed Number of Shares to Be Privately Placed	Use of Proceeds	Expected Benefits
15,000,000	1. To strengthen working capital – Ensuring stable operations and financial flexibility for the Company's ongoing activities. 2. To continue investment in new product development and related clinical trials – Supporting innovation, regulatory approvals, and future revenue growth. 3. To develop new markets – Expanding the Company's international presence and accelerating market penetration.	To accelerate the promotion of the Company's products in domestic and international markets, thereby increasing revenue and profitability.

3. The rights and obligations of the common shares to be privately placed under this proposal shall, in principle, be the same as those of the Company's existing common shares. However, except for the transferees permitted under Article 43-8 of the Securities and Exchange Act, the privately placed common shares shall not be transferred within three years from the delivery date. After the three-year restriction period, the Company may apply to the competent authority for retroactive public issuance and listing, provided that all relevant regulatory requirements are met.

4. The key terms of this proposal, including but not limited to the issue price discount rate, issue price, number of shares to be issued, total amount to be raised, project items, scheduled progress of fund utilization, anticipated benefits, and other related matters, shall be submitted to the shareholders' meeting for authorization of the Board of Directors to determine in light of market conditions and the Company's operational needs. If any amendment or revision is subsequently required by the competent authority or due to operational assessments, changes in objective circumstances, or changes in applicable laws or regulations, the Board of Directors is also authorized to handle such matters in full.

5. It is proposed that the Chairperson or his/her designated representative be authorized to act on behalf of the Company in signing and negotiating all agreements and documents related to this private placement and to take all necessary actions in connection therewith.

6. Whether any independent director expressed objections or reservations：No.

7. It is proposed that the shareholders' meeting authorize the Chairman or a designated representative to act on behalf of the Company in signing and negotiating all contracts and documents related to this private placement plan, and to handle all matters pertaining thereto.

8. Pursuant to Article 43-6 of the Securities and Exchange Act, the required disclosure items for this case are available on the Market Observation Post System website (https://mops.twse.com.tw). Please select "Private Placement Section" under "Special Topics." The information is also available on the Company's website (https://www.amcad.com.tw) by selecting "Shareholders' Meeting" under "Shareholders' Section" in the "Investor Relations" section.